市場調査レポート

商品コード

1619055

サイケデリック医薬品の市場規模、シェア、成長分析、ソース別、タイプ別、薬剤別、用途別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測、2024～2031年

Psychedelic Drugs Market Size, Share, Growth Analysis, By Source, By Type, By Drug, By Application, By Route of Administration, By End-User, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日: 2024年12月18日
発行: SkyQuest
ページ情報: 英文 242 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界のサイケデリック医薬品市場規模は2022年に16億米ドルと評価され、2023年の17億9,000万米ドルから2031年には44億7,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは12.1％で成長する見通しです。

サイケデリック医薬品市場は、メンタルヘルス治療の重要性に対する意識の高まりと、ストレスや不安などの問題に対処する必要性によって、大きな成長が見込まれています。サイケデリック医薬品の出現は、メンタルヘルス障害に対する革新的な治療選択肢を提供し、いくつかの課題にもかかわらず関心を集めています。2022 State of Mental Health in America（アメリカにおける精神衛生の現状）報告書などの最近のデータでは、若者の間で重度のうつ病の発症が増加していることが指摘されており、こうした治療への需要がさらに高まっています。政府の協力的な取り組みやメンタルヘルス啓発プログラムは、市場の拡大を後押しすると予想されます。厳しい規制と潜在的な副作用が制約となる一方で、この分野の受容拡大と研究開発の躍進は、今後数年間における投資と開発の主要分野として位置付けられます。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2023年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2021～2023年）

主要企業プロファイル

Pfizer Inc.（USA）
Johnson & Johnson（USA）
AbbVie Inc.（USA）
Jazz Pharmaceuticals（Ireland）
Compass Pathways（UK）
MindMed（Canada）
Atai Life Sciences（Germany）
Cybin Corp.（Canada）
Field Trip Health（Canada）
GH Research（Ireland）
Beckley Psytech（UK）
Seelos Therapeutics（USA）
Numinus Wellness Inc.（Canada）
Delix Therapeutics（USA）
Mydecine Innovations Group（Canada）
Revive Therapeutics Ltd.（Canada）
Entheon Biomedical（Canada）
Mind Cure Health Inc.（Canada）
PsyBio Therapeutics（USA）
Tryp Therapeutics（USA）

結論と推奨事項

Product Code: SQMIG35I2114

Global Psychedelic Drugs Market size was valued at USD 1.6 billion in 2022 and is poised to grow from USD 1.79 billion in 2023 to USD 4.47 billion by 2031, growing at a CAGR of 12.1% during the forecast period (2024-2031).

The psychedelic drug market is poised for significant growth, driven by heightened awareness of mental health treatment's importance and the need to address issues like stress and anxiety. The emergence of psychedelic drugs offers innovative treatment options for mental health disorders, attracting interest despite some challenges. Recent data, such as the 2022 State of Mental Health in America report, highlights a concerning rise in severe depressive episodes among youth, further fueling demand for these therapies. Collaborative government initiatives and mental health awareness programs are expected to bolster market expansion. While stringent regulations and potential side effects pose constraints, the sector's growing acceptance and research breakthroughs position it as a key area for investment and development in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Psychedelic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Psychedelic Drugs Market Segmental Analysis

Global Psychedelic Drugs Market is segmented by source, type, drug, application, route of administration, end-user, distribution channel and region. Based on source, the market is segmented into synthetic and natural. Based on type, the market is segmented into empathogens, dissociatives and others. Based on drug, the market is segmented into gamma-hydroxybutyric acid (GHB), ketamine, psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and others. Based on application, the market is segmented into narcolepsy, treatment-resistant depression, major depressive disorder, opiate addiction, post-traumatic stress disorder (PTSD) and others. Based on route of administration, the market is segmented into oral, inhalation and injectable. Based on end-user, the market is segmented into hospitals, specialty clinics, homecare and others. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Psychedelic Drugs Market

The global psychedelic drugs market is witnessing significant growth driven by the increasing acceptance of these substances for treating depression. Over the past decade, psychedelics have gained recognition for their therapeutic potential in mental health treatment, with researchers actively exploring their efficacy in alleviating symptoms of depression. Ongoing studies and advancements in psychedelic drug development have further enhanced their credibility and acceptance among healthcare professionals and patients alike. As promising results emerge from clinical trials, the popularity and demand for psychedelic therapies are surging, particularly in the United States and various other regions, positioning these factors as key market drivers.

Restraints in the Global Psychedelic Drugs Market

One significant constraint on the Global Psychedelic Drugs market is the elevated cost associated with these substances, which can hinder growth potential. The expensive nature of psychedelic drugs limits accessibility for many patients and consumers, potentially stifling widespread adoption and use. Moreover, the landscape is further complicated by stringent regulations and legal barriers, which can impede market expansion and innovation. These factors combined present challenges that the industry must navigate to achieve sustainable development and broader acceptance within the healthcare sector during the forecasted period. As a result, stakeholders must find solutions to alleviate these concerns for future market success.

Market Trends of the Global Psychedelic Drugs Market

The Global Psychedelic Drugs market is witnessing a notable trend towards the growth of hospital pharmacies, driven by heightened public consciousness surrounding mental health issues and the therapeutic potential of psychedelics. As these substances increasingly require prescriptions from medical professionals, hospital pharmacies are becoming essential distribution channels. This trend is further propelled by a growing body of research supporting the efficacy of psychedelics for specific indications, such as depression, anxiety, and PTSD. Consequently, stakeholders in the healthcare sector are prioritizing the integration of psychedelic therapies, thus fostering a dynamic environment for hospital pharmacies to expand their role in psychiatric treatment.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Patent Analysis
Case Studies
Customer & Buying Criteria Analysis

Global Psychedelic Drugs Market Size by Source & CAGR (2024-2031)

Market Overview
Synthetic
Natural

Global Psychedelic Drugs Market Size by Type & CAGR (2024-2031)

Market Overview
Empathogens
Dissociatives
Others

Global Psychedelic Drugs Market Size by Drug & CAGR (2024-2031)

Market Overview
Gamma-Hydroxybutyric Acid (GHB)
Ketamine
Psilocybin
Lysergic Acid Diethylamide (LSD)
3,4-Methylenedioxymethamphetamine (MDMA)
Others

Global Psychedelic Drugs Market Size by Application & CAGR (2024-2031)

Market Overview
Narcolepsy
Treatment-Resistant Depression
Major Depressive Disorder
Opiate Addiction
Post-Traumatic Stress Disorder (PTSD)
Others

Global Psychedelic Drugs Market Size by Route Of Administration & CAGR (2024-2031)

Market Overview
Oral
Inhalation
Injectable

Global Psychedelic Drugs Market Size by End-User & CAGR (2024-2031)

Market Overview
Hospitals
Specialty Clinics
Homecare
Others

Global Psychedelic Drugs Market Size by Distribution Channel & CAGR (2024-2031)

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Global Psychedelic Drugs Market Size & CAGR (2024-2031)

North America (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
- USA
- Canada
Europe (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Source, Type, Drug, Application, Route of Administration, End-User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jazz Pharmaceuticals (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Compass Pathways (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MindMed (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Atai Life Sciences (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cybin Corp. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Field Trip Health (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GH Research (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beckley Psytech (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seelos Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Numinus Wellness Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Delix Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mydecine Innovations Group (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Revive Therapeutics Ltd. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Entheon Biomedical (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mind Cure Health Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PsyBio Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tryp Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

サイケデリック医薬品の市場規模、シェア、成長分析、ソース別、タイプ別、薬剤別、用途別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測、2024～2031年

Psychedelic Drugs Market Size, Share, Growth Analysis, By Source, By Type, By Drug, By Application, By Route of Administration, By End-User, By Distribution Channel, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

サイケデリック医薬品市場規模：ソース別およびCAGR（2024～2031年）

サイケデリック医薬品市場規模：タイプ別およびCAGR（2024～2031年）

サイケデリック医薬品市場規模：薬剤別およびCAGR（2024～2031年）

サイケデリック医薬品市場規模：用途別およびCAGR（2024～2031年）

サイケデリック医薬品市場規模：投与経路別およびCAGR（2024～2031年）

サイケデリック医薬品市場規模：エンドユーザー別およびCAGR（2024～2031年）

サイケデリック医薬品市場規模：流通チャネル別およびCAGR（2024～2031年）

サイケデリック医薬品市場規模およびCAGR（2024～2031年）